Silence Therapeutics Plc ADRSLN
Price$10.71Intrinsic value$5.2851% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $615K-98.6% YoYTTM through 30 Jun 2026
Net Income -$60MTTM through 30 Jun 2026
Free Cash Flow -$42.3MTTM through 30 Jun 2026

Margins

Current
Gross Margin61.5%
Operating Margin-16,292.8%
Net Margin-9,748.5%

Returns

-142.2%ROE
-67.4%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio8.72x
Net Debt-$85Mnet cash position
Cash & Equivalents$72.1M

Quality Metrics

Altman Z-Score-2.20
Piotroski F-Score3 / 9
FCF Margin-6,872.5%
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'22'23'24'25
FY2025: $559K
Diluted EPS-$0.43TTM
'22'23'24'25
FY2025: $-0.63

Dividend

No dividend

Capital Allocation

Capex Intensity0.5%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.